Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone

Digestive and Liver Disease

Volumn 33, Issue 2, 2001, Pages 163-172

  Puoti, M ^a   Cadeo, G P ^a   Putzolu, V ^a   Forleo, M A ^a   Barni, M C ^a   Cristini, G ^a   Rossi, S ^a   Spinetti, A ^a   Zaltron, S ^a   Zanini, B ^a   Quiros Roldan, E ^a   Paraninfo, G ^a   Gargiulo, F ^a   Carosi, G ^a  

^a Department of Paediatrics   (Italy)

Author keywords

Hepatitis C Virus; Hepatitis C Virus kinetics; Hepatitis C Virus RNA

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FATIGUE; FEMALE; FEVER; GENOTYPE; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPOTHYROIDISM; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIVARIATE ANALYSIS; NAUSEA; NEUROPATHY; PILOT STUDY; PREDICTION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DEFECT; TREATMENT FAILURE; VIROLOGY;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; BIOPSY, NEEDLE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBABILITY; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 0035069022     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(01)80073-6     Document Type: Article

References (31)

1. Consensus statement
2. Natural history of chronic Hepatitis C
3. Interferon alfa-2b monotherapy versus interferon alfa 2b plus ribavirin as initial treatment for chronic hepatitis C: Results of US multicenter randomized controlled trial
4. Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis
5. Randomized trial of interferon alfa-2b plus Ribavirin for 48 weeks or for 24 weeks versus interferon alfa 2b plus placebo for 24 weeks versus interferon alfa-2b with and without ribavirin for treatment of chronic hepatitis C
6. New treatment strategies in non-responder patients with chronic hepatitis C
7. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C
8. Therapy of hepatitis C: Re-treatment with alpha interferon
9. Re-treatment of chronic hepatitis C with consensus interferon
10. Ribavirin enhances efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centres
11. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa resistant chronic hepatitis C
12. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience
13. Ribavirin and interferon-α combination therapy vs. interferon-α alone in the re-treatment of chronic hepatitis C: A randomized clinical trial
14. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to Interferon alone: Results of a randomized controlled trial
15. Interferon-α plus ribavirin in chronic hepatitis C resistant to previous interferon-α course: Results of a randomized multicenter trial
16. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment
17. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone
18. Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: A randomized trial
19. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a
20. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
21. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alpha
22. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
23. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
24. Treatment of chronic hepatitis C with interferon alfa n-3: A multicenter, randomized, open label trial
25. Daily interferon regimen for chronic hepatitis C. A prospective randomised study
26. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: A randomized multicenter trial
27. Response to higher doses of interferon alfa 2b in patients with chronic hepatitis C: A randomized multicenter trial
28. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis
29. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon
30. Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C
31. Is an "A la Carte" combination Interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?